LONDON. Three experimental vaccines against the Ebola virus are in advanced stages of development at UK laboratories, as health authorities accelerate efforts to contain a fresh outbreak in Central Africa. The outbreak, first detected in a remote region of the Democratic Republic of Congo three weeks ago, has so far claimed 12 lives, with 58 confirmed cases. The World Health Organisation has classified the event as a high-risk emergency, citing the proximity of affected areas to major transport hubs.
Scientists at the University of Oxford and Public Health England are leading the vaccine research, building on platforms developed during the 2014-2016 West African epidemic. Two of the candidates use viral vector technology, while a third employs a messenger RNA approach similar to that used in Covid-19 vaccines. All three have demonstrated robust immune responses in primate studies and are expected to enter Phase I human trials within six months, pending regulatory approval.
Health Secretary Jeremy Hunt confirmed that the government has allocated an additional 50 million pounds for outbreak response, including field hospitals, contact tracing teams, and diagnostic equipment. The UK is also deploying a Rapid Support Team of epidemiologists and virologists to the affected region in coordination with the WHO.
The news comes amid growing concern over the global supply of Ebola vaccines. The existing Merck vaccine, Ervebo, has proven effective but requires strict cold chain logistics. The new candidates aim to improve thermostability and ease of administration, potentially enabling broader use in resource-limited settings.
International health officials have praised the UK's rapid response but caution that containment will require sustained political will and funding. Dr. Michael Ryan, Executive Director of the WHO Health Emergencies Programme, stated that the outbreak "has the potential to become a major crisis if not brought under control quickly."
The UK's leadership in vaccine development reflects its broader strategy to maintain pandemic preparedness capabilities post-Brexit. The government has invested heavily in the Vaccine Taskforce, which has been repurposed for emerging threats since the end of the Covid-19 public health emergency.
As of this morning, no cases have been reported outside the DRC. However, neighbouring countries have activated surveillance systems. The UK Foreign Office has issued updated travel advice for the region, recommending against all but essential travel to affected areas.
